Literature DB >> 21968952

Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice.

Liu Zhongfa1, Ming Chiu, Jiang Wang, Wei Chen, Winston Yen, Patty Fan-Havard, Lisa D Yee, Kenneth K Chan.   

Abstract

PURPOSE: Curcumin has shown a variety of biological activity for various human diseases including cancer in preclinical setting. Its poor oral bioavailability poses significant pharmacological barriers to its clinical application. Here, we established a practical nano-emulsion curcumin (NEC) containing up to 20% curcumin (w/w) and conducted the pharmacokinetics of curcuminoids and curcumin metabolites in mice.
METHODS: This high loading NEC was formulated based on the high solubility of curcumin in polyethylene glycols (PEGs) and the synergistic enhancement of curcumin absorption by PEGs and Cremophor EL. The pharmacokinetics of curcuminoids and curcumin metabolites was characterized in mice using a LC-MS/MS method, and the pharmacokinetic parameters were determined using WinNonlin computer software.
RESULTS: A tenfold increase in the AUC (0→24h) and more than 40-fold increase in the C (max) in mice were observed after an oral dose of NEC compared with suspension curcumin in 1% methylcellulose. The plasma pharmacokinetics of its two natural congeners, demethoxycurcumin and bisdemethoxycurcumin, and three metabolites, tetrahydrocurcumin (THC), curcumin-O-glucuronide, and curcumin-O-sulfate, was characterized for the first time in mice after an oral dose of NEC.
CONCLUSION: This oral absorption enhanced NEC may provide a practical formulation to conduct the correlative study of the PK of curcuminoids and their pharmacodynamics, e.g., hypomethylation activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968952      PMCID: PMC3368221          DOI: 10.1007/s00280-011-1749-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  39 in total

1.  Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.

Authors:  Yan Gao; Zhonggang Li; Min Sun; Houli Li; Chenyu Guo; Jing Cui; Aiguo Li; Fengliang Cao; Yanwei Xi; Hongxiang Lou; Guangxi Zhai
Journal:  Drug Dev Ind Pharm       Date:  2010-10       Impact factor: 3.225

2.  Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells.

Authors:  Julia S Dempe; Erika Pfeiffer; Anne S Grimm; Manfred Metzler
Journal:  Mol Nutr Food Res       Date:  2008-09       Impact factor: 5.914

3.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.

Authors:  Anindita Mukerjee; Jamboor K Vishwanatha
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

4.  Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents.

Authors:  Hironori Ohtsu; Zhiyan Xiao; Junko Ishida; Masahiro Nagai; Hui-Kang Wang; Hideji Itokawa; Ching-Yuan Su; Charles Shih; Tzuying Chiang; Eugene Chang; YiFen Lee; Meng-Yin Tsai; Chawnshang Chang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2002-11-07       Impact factor: 7.446

5.  Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS).

Authors:  Deepa Patel; Krutika K Sawant
Journal:  Drug Dev Ind Pharm       Date:  2007-12       Impact factor: 3.225

Review 6.  Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent.

Authors:  Miguel López-Lázaro
Journal:  Mol Nutr Food Res       Date:  2008-06       Impact factor: 5.914

Review 7.  Highly active anticancer curcumin analogues.

Authors:  Cara A Mosley; Dennis C Liotta; James P Snyder
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

Review 8.  Clinical studies with curcumin.

Authors:  Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

9.  Curcumin is a potent DNA hypomethylation agent.

Authors:  Zhongfa Liu; Zhiliang Xie; William Jones; Ryan E Pavlovicz; Shujun Liu; Jianhua Yu; Pui-kai Li; Jiayuh Lin; Jame R Fuchs; Guido Marcucci; Chenglong Li; Kenneth K Chan
Journal:  Bioorg Med Chem Lett       Date:  2008-12-14       Impact factor: 2.823

10.  Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects.

Authors:  Shaiju K Vareed; Madhuri Kakarala; Mack T Ruffin; James A Crowell; Daniel P Normolle; Zora Djuric; Dean E Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

View more
  42 in total

1.  Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues.

Authors:  Andrew G Kunihiro; Julia A Brickey; Jennifer B Frye; Paula B Luis; Claus Schneider; Janet L Funk
Journal:  J Nutr Biochem       Date:  2018-10-11       Impact factor: 6.048

2.  Microparticles Containing Curcumin Solid Dispersion: Stability, Bioavailability and Anti-Inflammatory Activity.

Authors:  C C C Teixeira; L M Mendonça; M M Bergamaschi; R H C Queiroz; G E P Souza; L M G Antunes; L A P Freitas
Journal:  AAPS PharmSciTech       Date:  2015-06-04       Impact factor: 3.246

3.  Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.

Authors:  Abu Syed Md Anisuzzaman; Abedul Haque; Mohammad Aminur Rahman; Dongsheng Wang; James R Fuchs; Selwyn Hurwitz; Yuan Liu; Gabriel Sica; Fadlo R Khuri; Zhuo Georgia Chen; Dong M Shin; A R M Ruhul Amin
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

4.  Anti-inflammatory and Antioxidant Activity of Nanoencapsulated Curcuminoids Extracted from Curcuma longa L. in a Model of Cutaneous Inflammation.

Authors:  Emanuele P Lima; Odinei H Gonçalves; Franciele Q Ames; Lidiane V Castro-Hoshino; Fernanda V Leimann; Roberto K N Cuman; Jurandir F Comar; Ciomar A Bersani-Amado
Journal:  Inflammation       Date:  2020-11-09       Impact factor: 4.092

5.  Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Ashish Kumar Agrawal; Ramesh Gupta
Journal:  AAPS J       Date:  2017-10-18       Impact factor: 4.009

6.  Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin.

Authors:  Alex E Grill; Brenda Koniar; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

7.  Beta-Glucuronidase Catalyzes Deconjugation and Activation of Curcumin-Glucuronide in Bone.

Authors:  Andrew G Kunihiro; Paula B Luis; Julia A Brickey; Jen B Frye; H-H Sherry Chow; Claus Schneider; Janet L Funk
Journal:  J Nat Prod       Date:  2019-02-22       Impact factor: 4.050

8.  Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo.

Authors:  Kazuto Yasuda; Samit Ganguly; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2018-08-15       Impact factor: 3.922

Review 9.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

10.  Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice.

Authors:  Kwok Kin Cheng; Chin Fung Yeung; Shuk Wai Ho; Shing Fung Chow; Albert H L Chow; Larry Baum
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.